Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density

키워드

참고문헌 (38)

1. Haney AF, "Modern approaches to endometriosis", pp.113~128 (1991), Kluwer Academic
2. Howell R, "Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial", Fertil Steril, 64, pp.474~481 (1995)
3. McLachlan RI, "Clinical aspects of LHRH analogues in gynaecology: a review", Br J Obstet Gynaecol, 93, pp.431~454 (1986)
4. Erickson LD, "GnRH analogues in the treatment of endometriosis", Obstet Gynecol Clin North Am, 16, pp.123~145 (1989)
5. Meldrum DR, ""Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis", J Clin Endocrinol Metab, 54, pp.1081~1083 (1982)
6. Lemay A, "Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis", Fertil Steril, 41, pp.863~871 (1984)
7. Fogelman I, "Gonadotropin-releasing hormone agonists and the skeleton", Fertil Steril, 57, pp.715~724 (1992)
8. Lemay A, "Extending the use of gonadotropin-releasing hormone agonists: the emerging role of steroidal and nonsteroidal agents", Fertil Steril, 61, pp.21~34 (1994)
9. Orwoll ES, "Nafarelin therapy in endometriosis: long-term effects on bone mineral density", Am J Obstet Gynecol, 171, pp.1221~1225 (1994)
10. Crosignani P, "Advances in the management of endometriosis: an update for clinicians", Hum Reprod Update, 12, pp.179~189 (2006)
11. Surrey ES, "Steroidal and nonsteroidal "add-back" therapy: extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynecologic patient", Fertil Steril, 64, pp.673~685 (1995)
12. Pickersgill A, "GnRH agonists and add-back therapy: is there a perfect combination?", Br J Obstet Gynaecol, 105, pp.475~485 (1998)
13. Palomba S, "A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata", Fertil Steril, 70, pp.111~118 (1998)
14. Palomba S, "Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles", Fertil Steril, 72, pp.889~895 (1999)
15. Di Carlo C, "Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome", Fertil Steril, 75, pp.380~384 (2001)
16. Palomba S, "Effectiveness of short-term administration of tibolone plus gonadotropin-releasing hormone analogue on the surgical outcome of laparoscopic myomectomy", Fertil Steril, 75, pp.429~433 (2001)
17. Taskin O, "Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis", Fertil Steril, 67, pp.40~45 (1997)
18. Adashi EY, "Long-term gonadotrophin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms", Hum Reprod, 9, pp.1380~1397 (1994)
19. Kuiper GG, "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta", Endocrinology, 138, pp.863~870 (1997)
20. Khovidhunkit W, "Clinical effects of raloxifene hydrochloride in women", Ann Intern Med, 130, pp.431~439 (1999)
21. Walsh BW, "Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women", JAMA, 279, pp.1445~1451 (1998)
22. Ettinger B, "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators", JAMA, 282, pp.637~645 (1999)
23. Mosca L, "Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial", Ann N Y Acad Sci, 949, pp.181~185 (2001)
24. Barrett-Connor E, "Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial", JAMA, 287, pp.847~857 (2002)
25. Cummings SR, "The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation", JAMA, 281, pp.2189~2197 (1999)
26. Cohen FJ, "Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60", Obstet Gynecol, 95, pp.104~110 (2000)
27. Goldstein SR, "A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium", Obstet Gynecol, 95, pp.95~103 (2000)
28. Dawood MY, "Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol", Fertil Steril, 52, pp.21~26 (1989)
29. Whitehouse RW, "The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis", Clin Endocrinol, 33, pp.365~373 (1990)
30. Stevenson JC, "A comparison of the skeletal effects of goserelin and danazol in premenopausal women with endometriosis", Horm Res, 32(Suppl 1), pp.161~163 (1989)
31. Clemett D, "Raloxifene: a review of its use in postmenopausal osteoporosis", Drugs, 60, pp.379~411 (2000)
32. Díez JL, "Skeletal effects of selective oestrogen receptor modulators (SERMs)", Hum Reprod Update, 6, pp.255~258 (2000)
33. Prestwood KM, "A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women", J Clin Endocrinol Metab, 85, pp.2197~2202 (2000)
34. Lufkin EG, "Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial", J Bone Miner Res, 13, pp.1747~1754 (1998)
35. Meunier PJ, "Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group", Osteoporos Int, 10, pp.330~336 (1999)
36. Silverman SL, "The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study", Arthritis Rheum, 44, pp.2611~2619 (2001)
37. Palomba S, "Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism", J Clin Endocrinol Metab, 87, pp.4476~4481 (2002)
38. Finkelstein JS, "Bone mineral density changes during the menopause transition in a multiethnic cohort of women", J Clin Endocrinol Metab, 93, pp.861~868 (2008)

관련 논문AI추천